

The effect of cetylated fatty acid supplementation on low back pain

Submission date 05/04/2024	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 23/05/2024	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 03/03/2025	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data
		<input checked="" type="checkbox"/> Record updated in last year

Plain English Summary

Background and study aims

Low back pain is the leading contributor to disability in the U.S. with causes including degeneration of the spine, spinal stenosis, spondylolisthesis, and disc herniation. Current first-line treatment includes the use of NSAIDs to calm inflammation, however, these anti-inflammatories have demonstrated significant results alongside notable side effects of renal toxicity, GI side effects, and ulcers. Second-line treatment can extend to opioids in severe cases, which are not recommended due to patient dependence and addiction. Lastly, surgical interventions, such as spinal fusion and disc replacement, are last resort yet have high risks of complications, occurrence of pain, and continued use of NSAIDs despite intervention. Cetylated fatty acids (CFA) have been used to treat arthritis and sports injuries, mainly in hip, knee, and shoulder patients, as they are believed to reduce pain by decreasing the secretion of leukotriene B4 from stimulated neutrophils. There is an opportunity to apply CFA treatment to low back pain, in hopes of decreasing inflammation and providing a more optimal treatment for those who have adverse reactions to NSAIDs, opioids, or surgical intervention. This study aims to evaluate the effect of CFA supplementation on chronic, axial low back pain in patients over the age of 21 years old.

Who can participate?

Patients aged 21 years old and over with axial back pain from facet degenerative joint disease for more than 3 months will be recruited from a single center

What does the study involve?

Participants will take an oral supplementation two times a day and wear a patch for eight hours each day, over 30 days. Patients will fill out the questionnaires before and after taking the supplement to determine if CFAs ease back pain.

What are the possible benefits and risks of participating?

The benefits of participating in this trial include potential remission of low back pain symptoms such as stiffness, aching, and ambulation with a low side-effect profile supplement (i.e. cetylated fatty acids). The supplement has been shown to not induce adverse events such as GI ulcers, bleeding, or renal insufficiency, which can be found in mainstay treatment options, such as NSAIDs.

Documented risks of utilizing cetylated fatty acid supplementation include the potential for GI discomfort (flatulence, bloating), anaphylaxis, or skin irritation, as well as a patient not experiencing remission of symptoms.

Where is the study run from?
PharmaNutra Spa, Italy

When is the study starting and how long is it expected to run for?
April 2023 to December 2023

Who is funding the study?
PharmaNutra Spa, Italy

Who is the main contact?
Dr Vijay Vad, a Sports Medicine and PM&R physician at the Hospital for Special Surgeries,
vadv@hss.org

Contact information

Type(s)

Principal Investigator

Contact name

Dr Vijay Vad

Contact details

Hospital for Special Surgery (HSS), 523 East 72nd Street, 9th Floor
New York
United States of America
10021
+1 (212) 606-1306
vadv@hss.edu

Type(s)

Scientific

Contact name

Mr Antonio Madraza Ibarra

Contact details

Hospital for Special Surgery (HSS), 535 East 70th Street
New York
United States of America
10021
+1 (646) 797-8331
madraza@hss.edu

Type(s)

Public

Contact name

Ms Anjali Kashyap

Contact details

Hospital for Special Surgery (HSS), 523 East 72nd Street, 9th Floor

New York

United States of America

10021

+1 216-952-2747

anjali.kashyap@osumc.edu

Additional identifiers**EudraCT/CTIS number**

Nil known

IRAS number**ClinicalTrials.gov number**

Nil known

Secondary identifying numbers

Nil known

Study information**Scientific Title**

Effect of cetylated fatty acid supplementation on low back facet joint arthritis

Study hypothesis

The Cetilar Back Pain System will act synergistically to reduce axial back pain from facet degenerative joint disease

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 30/05/2023, Western Institutional Review Board (1019 39th Avenue SE Suite 120, Puyallup, WA, 98374, United States of America; +1 360-252-2500; clientservices@wirb.com), ref: 20230506

Study design

Prospective single-cohort study

Primary study design

Observational

Secondary study design

Cohort study

Study setting(s)

Home, Hospital, Medical and other records

Study type(s)

Quality of life, Treatment

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

Condition

Remediating chronic axial discogenic back pain

Interventions

This is a prospective observational study with 25 treated patients over the age of 21 years old with remediating chronic axial discogenic back pain, where patients will apply the Cetilar Back Pain System in two groups:

1. Cetilar stick oral formulation (Cetylated Fatty Acid 800mg - 10 ml) twice daily
2. Cetilar Patch (8 hours duration) every day for 30 days to analyze the effects of Cetylated Fatty Acid on low back pain

Intervention Type

Supplement

Primary outcome measure

Low back symptoms and pain measured using the Roland Morris Disability Questionnaire (RMDQ) pre-supplement and post-supplement after 30 days

Secondary outcome measures

The following secondary outcome measures are assessed pre- and post-supplement after 30 days:

1. Pain measured using the Numeric Pain Rating Scale (NPRS)
2. Adverse events measured using patient medical records at the end of the study
3. Treatment failure measured using patient medical records at the end of the study

Overall study start date

01/04/2023

Overall study end date

01/12/2023

Eligibility**Participant inclusion criteria**

1. Aged 21 years old and over
2. Axial back pain from facet degenerative joint disease for more than 3 months

Participant type(s)

Patient

Age group

Mixed

Lower age limit

21 Years

Upper age limit

100 Years

Sex

Both

Target number of participants

25

Participant exclusion criteria

1. Narcotic pain medication
2. Unwilling to follow study protocol
3. Pregnancy or currently breastfeeding
4. Low back pain from a traumatic injury
5. Currently using a pain patch (e.g lidocaine)

Recruitment start date

01/06/2023

Recruitment end date

01/09/2023

Locations**Countries of recruitment**

United States of America

Study participating centre

The Hospital for Special Surgery

523 East 72nd Street 9th Floor

New York

United States of America

10021

Sponsor information**Organisation**

PharmaNutra S.p.A.

Sponsor details

Via Delle Lenze, 216/b
Pisa
Italy
56122
+39 050 7846500
info@pharmanutra.it

Sponsor type

Industry

Website

<https://www.pharmanutra.it/en/>

Funder(s)**Funder type**

Industry

Funder Name

PharmaNutra S.p.A

Results and Publications**Publication and dissemination plan**

Planned publication in a peer-reviewed journal

Intention to publish date

31/03/2025

Individual participant data (IPD) sharing plan

The datasets generated during and analysed during the current study will be available upon request from the primary investigator, Dr Vijay Vad, vadv@hss.org. Raw data will be coded to avoid the identification of patients. Consent was both required and obtained from all participants.

IPD sharing plan summary

Available on request